Uncategorized

Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates

Published

on

Eli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unlikely to trigger a broad wave of Big Pharma deals.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version